Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:LASA

LASA SUPERGENERICS LTD

Healthcare › Pharmaceuticals & Biotechnology

Latest filings

  1. Routine Reg 74(5) compliance certificate for Sep 2026 quarter · Compliance
  2. Trading window closed for Q2 FY27 results · Compliance
  3. Annual Report FY26 and 11th AGM notice sent to shareholders · Results
All filings ↓
Ask Nexa about LASA SUPERGENERICS LTD

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹6 Cr over the trailing twelve months.

Market Cap
₹—
P / E (TTM)
—
EV / EBITDA
—
Div Yield
—
Growth
-34.1%▼
Revenue 5y CAGR
PAT — · EBITDA —
Quality
-19.8%·
ROCE (5y median)
ROE -22.5% (5y median) · margin -113.0%
Leverage
0.20·
Debt / Equity · low
Net debt ₹9.46 Cr
Revenue FY21→FY26
0.1×▼
Margin −146.9 pts
₹202 Cr → ₹25 Cr
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
ROCE#178/182
ROE#163/165
Debt / Equity#93/166
EBITDA margin#177/177
Revenue growth#155/161
Profit growth#44/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Negative working-capital cycle — the business is funded by its suppliers
Concerns
Revenue shrinking over 5 years (−34% a year)
Erratic profits — up in only 2 of the last 5 years
Negative returns on capital — −19.8% (5-year median)
#178 of 182 in Pharmaceuticals on the latest reported figures · down from 18.8% in FY21

Charts

How has the market priced it — with filings on the timeline?

LASA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from LASA SUPERGENERICS LTD's filed financials and exchange disclosures

What does LASA SUPERGENERICS LTD do?

LASA SUPERGENERICS LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol LASA.

Is LASA SUPERGENERICS LTD profitable?

No. Over the trailing twelve months LASA SUPERGENERICS LTD reported a net loss of ₹17 Cr on revenue of ₹6.36 Cr.

Does LASA SUPERGENERICS LTD pay a dividend?

Not in the latest reported year — LASA SUPERGENERICS LTD's dividend payout for FY26 was nil.

Is LASA SUPERGENERICS LTD debt-free?

No. It reported borrowings of ₹9.75 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹9.46 Cr after cash. Debt stands at 0.20× equity. That is higher than 56% of its 166 Pharmaceuticals peers.

Where can I track LASA SUPERGENERICS LTD's announcements?

Every NSE and BSE filing by LASA SUPERGENERICS LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.